Member Info for HotblackDesiato

Hi BillyB, I'm sure many here would appreciate your thoughts on where we're 'currently at' as a company; all quiet on 737, imminent completion of 1801 toxicology and potential new CNS compound(s). I quite understand if you don't want to speculate too much.

Regards.

Hi Laz - re the work with ReceptorAi, since it's a collaboration and not a "we've engaged..." or "we're employing...", I expect ReceptorAi to be getting something out of this deal other than money. Since they're a fairly new company, I think they may be using our data to help train their models/Ai in an area they've not fullt tapped into yet. They get to work with real-world data and we get what tumbles out the other end.

We might cover certain admin costs but I think using the word 'collaboration' suggests a 'you scratch my back and I'll scratch yours' sort of agreement.

When SP suggested they hoped to be able to give an update on 737 'not too far hence' from the date of the Proactive Investor presentation, I wonder if the statement was made in order to deliberately kick the 737 ball into the long grass, the sole intention being it buys them time while the 1801 trial completes. The presumption here being, IF someone informally suggested they'd make an offer for the whole company but only if 1801 tox is top notch, the BoD obviously can't announce that but they also knew they had to fill the news gap on 737 in some way. All things may dovetail nicely towards the end of the year. Or I'm overthinking (again).

As a slight aside re publishing in the British Journal of Pharmacology, if JR has submitted a paper on 1801 to the Journal then according to their own metrics for 2024, it takes (on average) -

Submission to first decision: 11 days

Submission to acceptance: 170 days

Acceptance to publication: 53 days

So around 7.5mths in total and keep in mind the acceptance rate is just 20%. On the bright side JR has penned enough successful patent applications that he should know how to present an academic paper.

Anyone holding their breath should have an oxygen tank on standby!

Hi OReilly - just to correct you, the collaboration isn't between Nvidia & SAR. ReceptorAi are using Nvidia's cloud application programming interface linked to their own tech to accelerate the number crunching/deep-learning required to discover/develop new drug compounds.

I wonder if it'd be worth SP tweeting the Nvidia link I originally posted as "an interesting article providing some background on the technology used by our new collaboration partner..."

Who knows, it might help reignite the sp ahead of any forthcoming news.

Morning Nav/C79 - looks like they have a friend at Google:

https://blog.google/around-the-globe/google-europe/25-new-startup-recipients-of-the-ukraine-support-fund/

At least ReceptorAi aren't using their GPUs for mining crypto -

https://developer.nvidia.com/blog/accelerating-drug-discovery-at-receptor-ai-with-nvidia-bionemo-cloud-apis/

Excellent self-control Bailiff, though I'll be very disappointed if the first trade on Tuesday isn't yours.

'Course, what we need now is for SP to tweet, "wouldn't want to be out of this over the long weekend".

Regards.

Hi Bailiff - I've topped up to a round number of shares a few times, always thinking it'd be my last buy. However it always turned out to be a temporary state of affairs as days, weeks or months later I'd decide to add again. Hoping we'll see significant returns one day, if currently holding 490,126 shares won't make you wealthy then another 9874 isn't going help.

That said, I look forward to your post tomorrow announcing your latest purchase :-)

This is not investment advice!

Hi LJ - just a thought - one other possibility is JR may have come up with another idea for an 1801-related patent meaning publication could be delayed. The BoD said that once the paper is in the public domain it becomes what is known as 'prior art' (see link below) and no further patents can be created.

https://en.wikipedia.org/wiki/Prior_art

Hi LJ - if you look at almost any article published in a science or medical journal, it's often many months between the submitted date, the accepted date and finally the published date. If the BoD announced it had been submitted but was then rejected, it'd look very bad. Better to wait until it's accepted or even delay in order to add toxicology data. As an addition, I wonder if it covers just the Oz trial or if it'll also include data re the covid trial.

It looks like the buying has dried up thanks to people seeing the surge towards 30p+ get wiped out by the large sales prior to the warrants. Those who bought near the recent high will feel locked-in and others who were considering buying are probably wary due to the possibility of similar events in the immediate future.

Only 4wks to go until the end of the tox trials so buying should pick up closer to that time.

Hi NavM - Sorry, yes, I could've worded my question better. Anyone who has been here long enough will know there are many bumps in the road to whopping returns. News on many fronts will trickle in and the sp should respond.

Regards.

Hi NavM - what makes you think the warrant holder(s) will sell all 1.4m shares? If they're smart they'll hang on to all their shares now and cash in when the sp reaches far greater heights.

The interesting thing in the RNS is it refers to, "... notices to exercise certain warrants...". Note the plural! Is it one person with warrants from different subscriptions or two people who happened to excercise their warrants at the same time?

Regards.

Hi Bailiff, per the RNS, "... the total number of ordinary shares in issue will be 136,815,933...", I think PCS was keeping his own tally that included outstanding warrants and the figure was closer to 150m (I think) if all are taken up.

Yeah Aber, probably correct in your assumptions. On the bright side, more money in the kitty for our future development - gotta take the rough with the smooth.

Hi C79 - interesting article on AI being used to design BBB-crossing molecules: https://arxiv.org/pdf/2407.00004

Regards.

Https://www.scientistlive.com/content/receptorai-announces-collaboration-sareum

If the holder intends to hang on to the shares will we see a TR-1 next week?

So was the large £88k trade a forward sell?